Previous 10 | Next 10 |
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...
Prothena (PRTA) announces the appointment of Sanjiv Patel to the company's board of directors.Patel is president and chief executive officer, and a member of the board of clinical-stage precision medicine company Relay Therapeutics.He most recently served as Allergan’s Execut...
DUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MB...
Prothena (PRTA): Q1 GAAP EPS of -$0.91 misses by $0.37.Revenue of $0.16M (+14.3% Y/Y) misses by $8.5M.Press Release For further details see: Prothena EPS misses by $0.37, misses on revenue
Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million provides funding to advance the R&D pipeline Announced confirmatory Phase 3 AFFIRM-AL study of birtamimab in Mayo Stage...
After initiating dosing in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease, Prothena Corporation (PRTA) has earned a milestone payment of $60M from Roche as part of its worldwide collaboration with the Swiss drugmaker.Involving ~575 subjects, Phase 2b...
DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $60 million milestone ...
DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it ...
Palm Beach, FL – May 4, 2021 – Cognitive assessment and training solutions and programs have been witnessing increasing demand due to rise in literacy rates and improved economic conditions among a growing population, especially in developing economies. These programs and test...
Prothena (PRTA) announces positive results from Phase 1 study of PRX004 in patients with hereditary ATTR Amyloidosis (hATTR). Slowing of neuropathy progression was demonstrated by a mean change of +1.29 points in NIS at 9 months, compared to +9.2 points in untreated and placebo-treated patien...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...